ArticleInternational urology and nephrology2026
Impact of continuous positive airway pressure therapy on metabolic and renal parameters in patients with obstructive sleep apnea, type 2 diabetes mellitus, and chronic kidney disease: a prospective cohort study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Future perspectives on the clinical implications of CPAP therapy in OSA-T2DM-CKD.International urology and nephrology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous positive airway pressure (CPAP) therapy is the gold standard treatment for obstructive sleep apnea (OSA), but its impact on type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), remains unclear. This study aimed to evaluate the effects of CPAP therapy on metabolic and renal parameters in patients with OSA, T2DM, and CKD for over 18 months. MATERIAL AND
methodsThis prospective, non-randomized, single-centre cohort study enrolled 60 patients with moderate-to-severe OSA (AHI > 15 episodes/hour), CKD (eGFR 15-60 mL/min/1.73m
results8 (13%) patients were lost to follow-up, and therefore 52 patients (27 patients in CPAP group and 25 patients in usual care group) were included in per-protocol analysis. After 18 months, CPAP therapy significantly improved AHI (mean change: 8.96 ± 4.94, p = 0.001), HbA1c (mean change: 1.44 ± 0.46, p = 0.001), HOMA-IR (mean change: 1.85 ± 0.14, p = 0.001), UACR (mean change: 139.08 ± 85.27 mg/g, p = 0.015), and serum creatinine (mean change: 1.02 ± 0.34 mg/dL, p = 0.011). No significant changes were observed in eGFR (p = 0.513) levels.
conclusionCPAP therapy significantly improved metabolic and renal parameters, particularly albuminuria and insulin resistance, in patients with OSA, T2DM, and CKD. However, it did not significantly impact the eGFR over 18 months.
Indexed as
Identifiers
40991192What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.